ABSTRACT
Pegvaliase-pqpz (Palynziq) is an enzyme substitution therapy FDA approved May 2018 to treat phenylketonuria in adults with blood phenylalanine levels greater than 600 µmol/L (10 mg/dL). Pegvaliase is administered via subcutaneous injection and carries a high risk of side effects including anaphylaxis. A consensus statement on its use recommends careful education and monitoring of patients. We established a dedicated Palynziq Clinic in October 2018 with detailed protocols to minimize these risks. In the first year, we evaluated 43 patients, initiated Palynziq in 37 and transitioned two trial patients to commercial drug. 13/37 patients (35.1%) have sustained blood phenylalanine levels <360 µmol/L (6 mg/dL) without adjunct sapropterin dihydrochloride treatment or medical food. The timing and dosage needed to achieve a response did not correlate with patient weight, starting phenylalanine level, starting diet, or co-treatment with sapropterin dihydrochloride. Some patients had consistently low phenylalanine levels <30 µmol/L (0.5 mg/dL) and required doses as low as 20 mg weekly. Anaphylactic episodes were reported by 21.6% (8/37 patients) versus 10% seen in the clinical trial. Rates of other side effects were similar to or less than those in the trial. Adverse reactions commonly occurred shortly after dosage increases. We provide a model for safely introducing and managing pegvaliase in adult patients with PKU.
Subject(s)
Ambulatory Care Facilities/statistics & numerical data , Drug-Related Side Effects and Adverse Reactions/prevention & control , Phenylalanine Ammonia-Lyase/therapeutic use , Phenylketonurias/drug therapy , Adolescent , Adult , Anaphylaxis/etiology , Anaphylaxis/prevention & control , Consensus , Female , Humans , Male , Middle Aged , Phenylalanine/blood , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/adverse effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Young AdultABSTRACT
Phenylketonuria (PKU), a deficiency in the activity of the enzyme phenylalanine hydroxylase, leads to toxic levels of phenylalanine (Phe) in the blood and brain. Pegvaliase (recombinant Anabaena variabilis phenylalanine ammonia lyase conjugated with polyethylene glycol) is approved to manage PKU in patients aged greater than or equal to 18 years in the United States and in patients aged greater than or equal to 16 years in the European Union. Pharmacokinetic, pharmacodynamic, and immunogenicity results from five open-label pegvaliase trials were assessed. Studies with induction/titration/maintenance (I/T/M) dosing regimens demonstrated pharmacokinetic stabilization and sustained efficacy associated with maintenance doses (20, 40, or 60 mg/day). Immune-mediated pegvaliase clearance was high during induction/titration phases when the early immune response was peaking. The combination of low drug dosage and high drug clearance led to low drug exposure and minimal decreases in blood Phe levels during induction/titration. Higher drug exposure and substantial reductions in blood Phe levels were observed later in treatment as drug clearance was reduced due to the maturation of the immune response, which allowed for increased dosing to target levels. The incidence of hypersensitivity reactions was temporally associated with the peaking of the early antidrug immune response and decreased with time as immune response matured after the first 6 months of treatment. These results support an I/T/M dosing regimen and suggest a strategy for administration of other nonhuman biologics to achieve efficacy and improve tolerability.
Subject(s)
Drug Hypersensitivity/epidemiology , Phenylalanine Ammonia-Lyase/pharmacokinetics , Phenylketonurias/drug therapy , Adult , Drug Hypersensitivity/etiology , Female , Humans , Incidence , Male , Phenylalanine/blood , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/adverse effects , Phenylketonurias/blood , Phenylketonurias/diagnosis , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Recombinant Proteins/pharmacokinetics , Treatment Outcome , United StatesABSTRACT
Engineered red blood cells (RBCs) appear to be a promising method for therapeutic drug and protein delivery. With a number of agents in clinical trials (e.g., dexamethasone 21-phosphate in ataxia telangiectasia, asparaginase in pancreatic cancer/acute lymphoblastic leukemia, thymidine phosphorylase in mitochondrial neurogastrointestinal encephalomyopathy, RTX-134 in phenylketonuria, etc.), this leading article summarizes the ongoing efforts in developing these agents, focuses on the clinical progress, and provides a brief background into engineered RBCs and the different ways in which they can be exploited for therapeutic/diagnostic purposes. References to available data on safety, efficacy, and tolerability are reported. Due to the continuous progress in this field, the information is updated as of January 2020 from databases, websites, and press releases of the involved companies and information that is in the public domain.
Subject(s)
Drug Carriers , Erythrocytes , Asparaginase/administration & dosage , Cell Engineering , Clinical Trials as Topic , Dexamethasone/administration & dosage , Humans , Phenylalanine Ammonia-Lyase/administration & dosage , Thymidine Phosphorylase/administration & dosageABSTRACT
Phenylalanine/tyrosine ammonia-lyases (PAL/TALs) have been approved by the FDA for treatment of phenylketonuria and may harbour potential for complementary treatment of hereditary tyrosinemia Type I. Herein, we explore ancestral sequence reconstruction as an enzyme engineering tool to enhance the therapeutic potential of PAL/TALs. We reconstructed putative ancestors from fungi and compared their catalytic activity and stability to two modern fungal PAL/TALs. Surprisingly, most putative ancestors could be expressed as functional tetramers in Escherichia coli and thus retained their ability to oligomerize. All ancestral enzymes displayed increased thermostability compared to both modern enzymes, however, the increase in thermostability was accompanied by a loss in catalytic turnover. One reconstructed ancestral enzyme in particular could be interesting for further drug development, as its ratio of specific activities is more favourable towards tyrosine and it is more thermostable than both modern enzymes. Moreover, long-term stability assessment showed that this variant retained substantially more activity after prolonged incubation at 25 °C and 37 °C, as well as an increased resistance to incubation at 60 °C. Both of these factors are indicative of an extended shelf-life of biopharmaceuticals. We believe that ancestral sequence reconstruction has potential for enhancing the properties of enzyme therapeutics, especially with respect to stability. This work further illustrates that resurrection of putative ancestral oligomeric proteins is feasible and provides insight into the extent of conservation of a functional oligomerization surface area from ancestor to modern enzyme.
Subject(s)
Dietary Supplements , Enzyme Replacement Therapy , Phenylalanine Ammonia-Lyase/therapeutic use , Tyrosinemias/therapy , Animals , Enzyme Activation , Enzyme Replacement Therapy/methods , Enzyme Stability , Fungi/classification , Fungi/enzymology , Fungi/genetics , Humans , Kinetics , Models, Molecular , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/chemistry , Phenylalanine Ammonia-Lyase/classification , Protein Conformation , Recombinant Proteins , Structure-Activity Relationship , Thermodynamics , Tyrosinemias/etiologyABSTRACT
In phenylketonuria (PKU), mutations of the phenylalanine hydroxylase (PAH) gene decrease the ability of PAH to convert phenylalanine (Phe) to tyrosine (Tyr), resulting in Phe accumulation in the blood and brain and disruption of neurotransmitter (NT) biosynthesis and metabolism. The following translational study explored the relationship between pegvaliase-mediated Phe correction in plasma and the NT biosynthesis and metabolism pathway in mice and humans with PKU. Lower plasma Phe levels were associated with normalization of the NT biosynthesis pathway which correlated with an improvement in inattention symptoms in subjects with PKU.
Subject(s)
Brain/metabolism , Neurotransmitter Agents/metabolism , Phenylalanine/blood , Phenylketonurias/metabolism , Amino Acids/metabolism , Animals , Biomarkers , Biosynthetic Pathways , Disease Models, Animal , Humans , Male , Mice , Mice, Knockout , Mutation , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Hydroxylase/genetics , Phenylketonurias/drug therapy , Phenylketonurias/genetics , Recombinant Proteins/administration & dosage , Treatment OutcomeABSTRACT
BACKGROUND: This study assessed the immunogenicity of pegvaliase (recombinant Anabaena variabilis phenylalanine [Phe] ammonia lyase [PAL] conjugated with polyethylene glycol [PEG]) treatment in adults with phenylketonuria (PKU) and its impact on safety and efficacy. METHODS: Immunogenicity was assessed during induction, upward titration, and maintenance dosing regimens in adults with PKU (nâ¯=â¯261). Total antidrug antibodies (ADA), neutralizing antibodies, immunoglobulin (Ig) M and IgG antibodies against PAL and PEG, IgG and IgM circulating immune complex (CIC) levels, complement components 3 and 4 (C3/C4), plasma Phe, and safety were assessed at baseline and throughout the study. Pegvaliase-specific IgE levels were measured in patients after hypersensitivity adverse events (HAE). FINDINGS: All patients developed ADA against PAL, peaking by 6â¯months and then stabilizing. Most developed transient antibody responses against PEG, peaking by 3â¯months, then returning to baseline by 9â¯months. Binding of ADA to pegvaliase led to CIC formation and complement activation, which were highest during early treatment. Blood Phe decreased over time as CIC levels and complement activation declined and pegvaliase dosage increased. HAEs were most frequent during early treatment and declined over time. No patient with acute systemic hypersensitivity events tested positive for pegvaliase-specific IgE near the time of the event. Laboratory evidence was consistent with immune complex-mediated type III hypersensitivity. No evidence of pegvaliase-associated IC-mediated end organ damage was noted. INTERPRETATION: Despite a universal ADA response post-pegvaliase administration, adult patients with PKU achieved substantial and sustained blood Phe reductions with a manageable safety profile. FUND: BioMarin Pharmaceutical Inc.
Subject(s)
Antibodies , Antigen-Antibody Complex , Drug Hypersensitivity , Phenylalanine Ammonia-Lyase , Phenylketonurias , Recombinant Proteins , Adult , Antibodies/blood , Antibodies/immunology , Antigen-Antibody Complex/blood , Antigen-Antibody Complex/immunology , Complement C3/immunology , Complement C3/metabolism , Complement C4/immunology , Complement C4/metabolism , Drug Hypersensitivity/blood , Drug Hypersensitivity/immunology , Female , Humans , Male , Phenylalanine/blood , Phenylalanine/immunology , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/adverse effects , Phenylketonurias/blood , Phenylketonurias/drug therapy , Phenylketonurias/immunology , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effectsABSTRACT
BACKGROUND: Phenylketonuria (PKU) is caused by a deficiency in phenylalanine hydroxylase enzyme activity that leads to phenylalanine (Phe) accumulation in the blood and brain. Elevated blood Phe levels are associated with complications in adults, including neurological, psychiatric, and cognitive issues. Even with nutrition and pharmacological management, the majority of adults with PKU do not maintain blood Phe levels at or below guideline recommended levels. Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammonia, and is an investigational enzyme substitution therapy to lower blood Phe in adults with PKU. METHODS: Pegvaliase was administered using an induction, titration, and maintenance dosing regimen in adults with PKU naïve to pegvaliase treatment. Doses were gradually increased until blood Pheâ¯≤â¯600⯵mol/L was achieved. The maintenance dose was the dose at which participants achieved and sustained blood Pheâ¯≤â¯600⯵mol/L for at least 4â¯weeks without dose modification. Analyses were performed for participants who achieved (Group A, nâ¯=â¯11) and did not achieve (Group B, nâ¯=â¯13) maintenance dose during the first 24â¯weeks of study treatment. RESULTS: Baseline mean blood Phe for Group A and Group B were 1135⯵mol/L and 1198⯵mol/L, respectively. Mean blood Pheâ¯≤â¯600⯵mol/L was achieved for Group A by Week 11 (mean blood Phe of 508⯱â¯483⯵mol/L) and for Group B by Week 48 (mean blood Phe of 557⯱â¯389⯵mol/L). The most common adverse events involved hypersensitivity reactions, which were mostly mild to moderate in severity and decreased over time. One participant in Group B had four acute systemic hypersensitivity events of anaphylaxis consistent with clinical National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network criteria; all events were non-IgE mediated and resolved without sequelae, with pegvaliase dosing discontinued after the fourth event. The incidence and titers of anti-drug antibodies were generally lower in Group A compared to Group B. CONCLUSIONS: Pegvaliase administered with an induction, titration, and maintenance dosing regimen demonstrated substantial efficacy at reducing blood Phe in both Group A and Group B by Week 48, with a manageable safety profile in most participants. Blood Phe reduction due to pegvaliase appears to be related to dose, treatment duration, and individual immune response; given additional time on treatment and dose titration, later Phe responders (Group B) achieved benefit similar to early Phe responders (Group A), with similar long-term safety profiles.
Subject(s)
Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine/blood , Phenylketonurias/drug therapy , Recombinant Proteins/administration & dosage , Adolescent , Adult , Aged , Antibodies/blood , Diagnostic Tests, Routine , Dose-Response Relationship, Drug , Female , Humans , Male , Middle Aged , Phenylalanine Ammonia-Lyase/chemistry , Phenylketonurias/blood , Phenylketonurias/pathology , Recombinant Proteins/chemistry , Young AdultABSTRACT
BioMarin Pharmaceutical is developing pegvaliase (PALYNZIQ™) as a treatment for phenylketonuria, a genetic disorder caused by deficiency of phenylalanine hydroxylase which leads to neurotoxic accumulation of phenylalanine. Data from the phase III PRISM clinical trial program indicate treatment with pegvaliase is associated with sustained reductions in blood phenylalanine levels and sustained improvements in neurological sequelae in patients with phenylketonuria. Based on these positive results pegvaliase was recently approved in the US for adults with phenylketonuria who have uncontrolled blood phenylalanine concentrations on current treatment. This article summarizes the milestones in the development of pegvaliase leading to this first approval.
Subject(s)
Phenylalanine Ammonia-Lyase/adverse effects , Phenylalanine Ammonia-Lyase/therapeutic use , Phenylketonurias/drug therapy , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Animals , Clinical Trials, Phase III as Topic , Drug Approval , Humans , Patents as Topic , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/pharmacokinetics , Recombinant Proteins/administration & dosage , Recombinant Proteins/pharmacokineticsABSTRACT
Untreated phenylketonuria (PKU) results in severe neurodevelopmental disorders, which can be partially prevented by an early and rigorous limitation of phenylalanine (Phe) intake. Enzyme substitution therapy with recombinant Anabaena variabilis Phe Ammonia Lyase (rAvPAL) proved to be effective in reducing blood Phe levels in preclinical and clinical studies of adults with PKU. Aims of present study were: a) to gather proofs of clinical efficacy of rAvPAL treatment in preventing neurological impairment in an early treated murine model of PKU; b) to test the advantages of an alternative delivering system for rAvPAL such as autologous erythrocytes. BTBR-Pahenu2-/- mice were treated from 15 to 64 post-natal days with weekly infusions of erythrocytes loaded with rAvPAL. Behavioral, neurochemical, and brain histological markers denoting untreated PKU were examined in early treated adult mice in comparison with untreated and wild type animals. rAvPAL therapy normalized blood and brain Phe; prevented cognitive developmental failure, brain depletion of serotonin, dendritic spine abnormalities, and myelin basic protein reduction. No adverse events or inactivating immune reaction were observed. In conclusion present study testifies the clinical efficacy of rAvPAL treatment in a preclinical model of PKU and the advantages of erythrocytes as carrier of the enzyme in term of frequency of the administrations and prevention of immunological reactions.
Subject(s)
Drug Delivery Systems , Intellectual Disability/prevention & control , Phenylalanine Ammonia-Lyase/therapeutic use , Phenylketonurias/drug therapy , Recombinant Proteins/therapeutic use , Administration, Intravenous , Anabaena/enzymology , Animals , Brain Chemistry , Disease Models, Animal , Drug Evaluation, Preclinical , Erythrocytes , Female , Intellectual Disability/etiology , Male , Mice , Mice, Knockout , Motor Activity , Phenylalanine/analysis , Phenylalanine/blood , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylketonurias/complications , Recombinant Proteins/administration & dosageABSTRACT
BACKGROUND: Phenylketonuria (PKU) is caused by phenylalanine hydroxylase (PAH) deficiency that results in phenylalanine (Phe) accumulation. Pegvaliase, PEGylated recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL), converts Phe to trans-cinnamic acid and ammonia, and is a potential enzyme substitution therapy to lower blood Phe in adults with PKU. METHODS: Two Phase 3 studies, PRISM-1 and PRISM-2, evaluated the efficacy and safety of pegvaliase treatment using an induction, titration, and maintenance dosing regimen in adults with PKU. In PRISM-1, pegvaliase-naïve participants with blood Phe >600⯵mol/L were randomized 1:1 to a maintenance dose of 20â¯mg/day or 40â¯mg/day of pegvaliase. Participants in PRISM-1 continued pegvaliase treatment in PRISM-2, a 4-part clinical trial that includes an ongoing, open-label, long-term extension study of pegvaliase doses of 5â¯mg/day to 60â¯mg/day. RESULTS: Of 261 participants who received pegvaliase treatment, 72.0% and 32.6% reached ≥12â¯months andâ¯≥â¯24â¯months of study treatment, respectively, and 65% are still actively receiving treatment. Mean (SD) blood Phe was 1232.7 (386.4) µmol/L at baseline, 564.5 (531.2) µmol/L at 12â¯months, and 311.4 (427) µmol/L at 24â¯months, a decrease from baseline of 51.1% and 68.7%, respectively. Within 24â¯months, 68.4% of participants achieved blood Phe ≤600⯵mol/L, 60.7% of participants achieved blood Phe ≤360⯵mol/L, below the upper limit recommended in the American College of Medical Genetics and Genomics PKU management guidelines, and 51.2% achieved blood Phe ≤120⯵mol/L, below the upper limit of normal in the unaffected population. Improvements in neuropsychiatric outcomes were associated with reductions in blood Phe and were sustained with long-term pegvaliase treatment. Adverse events (AEs) were more frequent in the first 6â¯months of exposure (early treatment phase) than after 6â¯months of exposure (late treatment phase); 99% of AEs were mild or moderate in severity and 96% resolved without dose interruption or reduction. The most common AEs were arthralgia (70.5%), injection-site reaction (62.1%), injection-site erythema (47.9%), and headache (47.1%). Acute systemic hypersensitivity events consistent with clinical National Institute of Allergy and Infectious Diseases and the Food Allergy and Anaphylaxis Network anaphylaxis criteria were observed in 12 participants (17 events); of these, 6 participants remained on treatment. Acute systemic hypersensitivity events including potential events of anaphylaxis were not associated with immunoglobulin E, and all events resolved without sequelae. CONCLUSION: Results from the PRISM Phase 3 program support the efficacy of pegvaliase for the treatment of adults with PKU, with a manageable safety profile in most participants. The PRISM-2 extension study will continue to assess the long-term effects of pegvaliase treatment.
Subject(s)
Phenylalanine Ammonia-Lyase/therapeutic use , Phenylalanine/blood , Phenylketonurias/drug therapy , Recombinant Proteins/therapeutic use , Adult , Female , Humans , Male , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/adverse effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Time Factors , Young AdultABSTRACT
INTRODUCTION: Pegvaliase is a recombinant Anabaena variabilis phenylalanine ammonia lyase (PAL) enzyme under investigation for treatment of adult phenylketonuria (PKU). This manuscript describes results of a randomized discontinuation trial (RDT) designed to evaluate the effects of pegvaliase treatment on blood phenylalanine (Phe) and neuropsychiatric outcomes in adults with PKU. METHODS: PRISM-2 is a 4-part, Phase 3 study that enrolled adults with PKU receiving pegvaliase treatment (initiated in a prior Phase 2 or Phase 3 study). The RDT, Part 2 of PRISM-2, was an 8-week trial that evaluated change in blood Phe concentrations, neuropsychiatric and neurocognitive measures, and safety outcomes in PRISM-2 participants who had achieved at least a 20% blood Phe reduction from pre-treatment baseline with pegvaliase treatment. Participants were randomized 2:1 to either continue pegvaliase (20â¯mg/day or 40â¯mg/day) or switch to matching placebo. RESULTS: The pooled pegvaliase group enrolled 66 participants and each placebo group enrolled 14 participants. The primary endpoint of change in blood Phe concentration from RDT entry to RDT Week 8 was met with clinically meaningful and statistically significant differences between the pegvaliase and placebo groups. Mean (SD) blood Phe at the beginning of the RDT when all participants were receiving pegvaliase was 563.9⯵M (504.6) in the group assigned to the 20â¯mg/day placebo group (nâ¯=â¯14), 508.2⯵M (363.7) in those assigned to the 40â¯mg/day placebo group (nâ¯=â¯14), and 503.9⯵M (520.3) in those assigned to continue pegvaliase treatment (nâ¯=â¯58). At Week 8 of the RDT, the least squares mean change (95% confidence interval) in blood Phe was 949.8⯵M (760.4 to 1139.1) for the 20â¯mg/day placebo group and 664.8⯵M (465.5 to 864.1) for the 40â¯mg/day placebo group in comparison to 26.5⯵M (-68.3 to 121.3) for the pooled (20â¯mg/day and 40â¯mg/day) pegvaliase group (Pâ¯<â¯0.0001 for pooled pegvaliase group vs each placebo group). Adverse events (AEs) were usually lower in the pooled placebo group when compared to the pooled pegvaliase group. The most common AEs for the pooled pegvaliase and pooled placebo groups were arthralgia (13.6% and 10.3%, respectively), headache (12.1% and 24.1%), anxiety (10.6% and 6.9%), fatigue (10.6% and 10.3%), and upper respiratory tract infection (1.5% and 17.2%). CONCLUSION: Mean blood Phe reduction was sustained in the pegvaliase group, while placebo groups had mean blood Phe concentration increase toward pre-treatment baseline levels. Results from this study confirmed the efficacy of pegvaliase in maintaining reduced blood Phe concentrations with a manageable safety profile for most participants.
Subject(s)
Phenylalanine Ammonia-Lyase/therapeutic use , Phenylalanine/blood , Phenylketonurias/drug therapy , Recombinant Proteins/therapeutic use , Adolescent , Adult , Dietary Proteins , Double-Blind Method , Female , Humans , Male , Middle Aged , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/adverse effects , Recombinant Proteins/administration & dosage , Recombinant Proteins/adverse effects , Young AdultABSTRACT
Pegylated recombinant phenylalanine ammonia lyase (pegvaliase) is an enzyme substitution therapy being evaluated for the treatment of phenylketonuria (PKU). PKU is characterized by elevated plasma phenylalanine, which is thought to lead to a deficiency in monoamine neurotransmitters and ultimately, neurocognitive dysfunction. A natural history evaluation in a mouse model of PKU demonstrated a profound decrease in tyrosine hydroxylase (TH) immunoreactivity in several brain regions, beginning at 4weeks of age. Following treatment with pegvaliase, the number of TH positive neurons was increased in several brain regions compared to placebo treated ENU2 mice.
Subject(s)
Phenylalanine Ammonia-Lyase/therapeutic use , Phenylketonurias/complications , Phenylketonurias/drug therapy , Animals , Brain/drug effects , Brain/enzymology , Brain/pathology , Disease Models, Animal , Humans , Mice , Neurotransmitter Agents/administration & dosage , Neurotransmitter Agents/genetics , Neurotransmitter Agents/therapeutic use , Phenylalanine/blood , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/genetics , Phenylketonurias/pathology , Phenylketonurias/physiopathology , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Tyrosine 3-Monooxygenase/immunology , Tyrosine 3-Monooxygenase/metabolismABSTRACT
CONTEXT: Phenylketonuria (PKU) is the most common hereditary defect of phenylalanine hydroxylase (PAH) enzyme achieving the hydroxylation of phenylalanine (Phe). Phenylalanine ammonia lyase (PAL) converts Phe to a harmless metabolite, trans-cinnamic acid (TCA) in plants and PAL enzyme activity is fairly high in plants rich in flavonoids. OBJECTIVE: The study aimed the biochemical analysis of PAL form Centaurea depressa BIEB. (Asteraceae) a flavonoid rich plant. This study may form the main frame of future research efforts for the development of a plant preparation aimed for oral intake in PKU patients in an attempt to enrich their diet by allowing them to ingest some food stuff containing Phe without being exposed to complications. MATERIALS AND METHODS: PAL was partially purified from the leaves of C. depressa. Enzyme activity was determined in comparison with that of other herbs that reportedly have a high PAL activity. Enzyme optimization was achieved and the PAL protein was detected by western blotting. RESULTS: C. depressa PAL demonstrated high activity (34.9 ± 0.6 U/mg protein). The enzyme was purified by 1.92-fold, which resulted in an activity of 53.30 ± 0.2 U/mg protein. The high-performance liquid chromatography analyzes of the PAL activity both before and after purification were in agreement. Western blot of PAL exhibited a 70 kDa protein band. The optimum pH and temperature are pH 8.8 and 37 °C. The optimum activities under gastric and intestinal digestion conditions were observed at pH 4.0 and pH 8.0, respectively. DISCUSSION AND CONCLUSION: PAL activity of C. depressa is high, and does not disappear under different environmental conditions. This enzyme could be used for the development of dietary foods and biotechnological products for patients with PKU.
Subject(s)
Centaurea/chemistry , Centaurea/enzymology , Phenylalanine Ammonia-Lyase/metabolism , Phenylketonurias/enzymology , Plant Extracts/metabolism , Administration, Oral , Dose-Response Relationship, Drug , Enzyme Activation/physiology , Humans , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylketonurias/drug therapy , Plant Extracts/isolation & purification , Plant Extracts/therapeutic useABSTRACT
BACKGROUND: Seedling roots of anthocyanin-rich corn (Zea mays) cultivars contain high levels of phenylalanine ammonia lyase (PAL) activity. The development of a natural dietary supplement containing corn roots could provide the means to improve the restrictive diet of phenylketonuria (PKU) patients by increasing their tolerance to dietary phenylalanine (Phe). Therefore this research was undertaken to explore the sensory characteristics of roots of four corn cultivars as well as to develop and evaluate food products (cereal bar, beverage, jam-like spread) to which roots had been added. RESULTS: Sensory profiles of corn roots were investigated using ten trained judges. Roots of Japanese Striped corn seedlings were more bitter, pungent and astringent than those of white and yellow cultivars, while roots from the Blue Jade cultivar had a more pronounced earthy/mushroom aroma. Consumer research using 24 untrained panelists provided hedonic (degree-of-liking) assessments for products with and without roots (controls). The former had lower mean scores than the controls; however, the cereal bar had scores above 5 on the nine-point scale for all hedonic assessments compared with the other treated products. CONCLUSION: By evaluating low-Phe food products containing corn roots, this research ascertained that the root-containing low-Phe cereal bar was an acceptable 'natural' dietary supplement for PKU-affected individuals.
Subject(s)
Dietary Supplements , Food, Formulated/analysis , Phenylalanine Ammonia-Lyase/pharmacology , Phenylalanine/metabolism , Phenylketonurias/diet therapy , Plant Roots/chemistry , Zea mays/chemistry , Anthocyanins/metabolism , Edible Grain , Humans , Odorants , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/metabolism , Phenylalanine Hydroxylase/metabolism , Plant Roots/enzymology , Plant Roots/metabolism , Seedlings/chemistry , Seedlings/enzymology , Seedlings/metabolism , Taste , Zea mays/enzymology , Zea mays/metabolismABSTRACT
Phenylketonuria (PKU) is an autosomal recessive genetic disease caused by defects in the phenylalanine hydroxylase gene. Preclinical and clinical investigations suggest that phenylalanine ammonia lyase (PAL) could be an effective alternative for the treatment of PKU. The aim of this study is to investigate if erythrocytes loaded with PAL may act as a safe delivery system able to overcome bioavailability issues and to provide, in vivo, a therapeutically relevant concentration of enzyme. Murine erythrocytes were loaded with recombinant PAL from Anabaena variabilis (rAvPAL) and their ability to perform as bioreactors was assessed in vivo in adult BTBR-Pah(enu2) mice, the genetic murine model of PKU. Three groups of mice were treated with a single i.v. injection of rAvPAL-RBCs at three different doses to select the most appropriate one for assessment of efficacy. Repeated administrations at 9-10 day-intervals of the selected dose for 10 weeks showed that the therapeutic effect was persistent and not affected by the generation of antibodies induced by the recombinant enzyme. This therapeutic approach deserves further in vivo evaluation either as a potential option for the treatment of PKU patients or as a possible model for the substitutive enzymatic treatment of other inherited metabolic disorders.
Subject(s)
Enzyme Replacement Therapy/methods , Erythrocytes/metabolism , Phenylalanine Ammonia-Lyase/therapeutic use , Phenylketonurias/drug therapy , Animals , Biological Availability , Dose-Response Relationship, Drug , Drug Carriers , Drug Delivery Systems , Humans , Immunoglobulin G/analysis , Mice , Mice, Inbred Strains , Phenylalanine/metabolism , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylketonurias/genetics , Recombinant Proteins/therapeutic useABSTRACT
BACKGROUND: Phenylketonuria is an inherited disease caused by impaired activity of phenylalanine hydroxylase, the enzyme that converts phenylalanine to tyrosine, leading to accumulation of phenylalanine and subsequent neurocognitive dysfunction. Phenylalanine ammonia lyase is a prokaryotic enzyme that converts phenylalanine to ammonia and trans-cinnamic acid. We aimed to assess the safety, tolerability, pharmacokinetic characteristics, and efficacy of recombinant Anabaena variabilis phenylalanine ammonia lyase (produced in Escherichia coli) conjugated with polyethylene glycol (rAvPAL-PEG) in reducing phenylalanine concentrations in adult patients with phenylketonuria. METHODS: In this open-label, phase 1, multicentre trial, single subcutaneous injections of rAvPAL-PEG were given in escalating doses (0·001, 0·003, 0·010, 0·030, and 0·100 mg/kg) to adults with phenylketonuria. Participants aged 18 years or older with blood phenylalanine concentrations of 600 µmol/L or higher were recruited from among patients attending metabolic disease clinics in the USA. The primary endpoints were safety and tolerability of rAvPAL-PEG. Secondary endpoints were the pharmacokinetic characteristics of the drug and its effect on concentrations of phenylalanine. Participants and investigators were not masked to assigned dose group. This study is registered with ClinicalTrials.gov, number NCT00925054. FINDINGS: 25 participants were recruited from seven centres between May 6, 2008, and April 15, 2009, with five participants assigned to each escalating dose group. All participants were included in the safety population. The most frequently reported adverse events were injection-site reactions and dizziness, which were self-limited and without sequelae. Two participants had serious adverse reactions to intramuscular medroxyprogesterone acetate, a drug that contains polyethylene glycol as an excipient. Three of five participants given the highest dose of rAvPAL-PEG (0·100 mg/kg) developed a generalised skin rash. By the end of the study, all participants had developed antibodies against polyethylene glycol, and some against phenylalanine ammonia lyase as well. Drug concentrations peaked about 89-106 h after administration of the highest dose. Treatment seemed to be effective at reducing blood phenylalanine in all five participants who received the highest dose (mean reduction of 54·2% from baseline), with a nadir about 6 days after injection and an inverse correlation between drug and phenylalanine concentrations in plasma. Phenylalanine returned to near-baseline concentrations about 21 days after the injection. INTERPRETATION: Subcutaneous administration of rAvPAL-PEG in a single dose of up to 0·100 mg/kg was fairly safe and well tolerated in adult patients with phenylketonuria. At the highest dose tested, rAvPAL-PEG reduced blood phenylalanine concentrations. In view of the development of antibodies against polyethylene glycol (and in some cases against phenylalanine ammonia lyase), future studies are needed to assess the effect of repeat dosing. FUNDING: BioMarin Pharmaceutical.
Subject(s)
Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/pharmacology , Phenylalanine/blood , Phenylketonurias/drug therapy , Polyethylene Glycols/administration & dosage , Adult , Drug Administration Schedule , Female , Humans , Injections, Subcutaneous , Male , Phenylalanine Ammonia-Lyase/immunology , Phenylketonurias/blood , Time Factors , Treatment Outcome , United StatesABSTRACT
Phenylketonuria (PKU) is an inherited metabolic disorder caused by deficient phenylalanine hydroxylase (PAH) activity, the enzyme responsible for the disposal of excess amounts of the essential amino acid phenylalanine (Phe). Phenylalanine ammonia-lyase (PAL, EC 4.3.1.5) has potential to serve as an enzyme substitution therapy for this human genetic disease. Using 7-day-old Japanese Striped corn seedlings (Japonica Striped maize, Zea mays L. cv. japonica) that contain high activities of PAL, we investigated a number of methods to preserve the roots as an intact food and for long-term storage. The cryoprotectant effects of maple syrup and other edible sugars (mono- and oligosaccharides) were evaluated. Following thawing, the preserved roots were then examined to determine whether the rigid plant cell walls could protect the PAL enzyme from proteolysis during simulated (in vitro) digestion comprised of gastric and intestinal phases. While several treatments led to retention of PAL activity during freezing, upon thawing and in vitro digestion, root tissues that had been previously frozen in the presence of maple syrup exhibited the highest residual PAL activities (â¼50% of the initial enzyme activity), in marked contrast to all of the treatments using other edible sugars. The structural integrity of the root cells, and the stability of the functional PAL tetramer were also preserved with the maple syrup protocol. These results have significance for the formulation of oral enzyme/protein therapeutics. When plant tissues are adequately preserved, the rigid cell walls constitute a protective barrier even under harsh (e.g. gastrointestinal-like) conditions.
Subject(s)
Cryopreservation/methods , Phenylalanine Ammonia-Lyase/metabolism , Seedlings/enzymology , Zea mays/enzymology , Cryoprotective Agents/metabolism , Enzyme Therapy , Humans , Phenylalanine Ammonia-Lyase/administration & dosage , Phenylalanine Ammonia-Lyase/therapeutic use , Phenylketonurias/drug therapy , Seedlings/physiology , Zea mays/physiologyABSTRACT
Phenylketonuria (PKU), a Mendelian autosomal recessive phenotype (OMIM 261600), is an inborn error of metabolism causing impaired postnatal cognitive development in the absence of treatment. We used the Pah(enu2/enu2) PKU mouse model to study oral enzyme substitution therapy with various chemically modified formulations of phenylalanine ammonia lyase (Av-p.C503S/p.C565S/p.F18A PAL). In vivo studies with the most therapeutically effective formulation (5kDa PEG-Av-p.C503S/p.C565S/p.F18A PAL) revealed that this conjugate, given orally, yielded statistically significant (p=0.0029) and therapeutically relevant reduction (~40%) in plasma phenylalanine (Phe) levels. Phe reduction occurred in a dose- and loading-dependent manner; sustained clinically and statistically significant reduction of plasma Phe levels was observed with treatment ranging between 0.3 IU and 9 IU and with more frequent and smaller dosings. Oral PAL therapy could potentially serve as an adjunct therapy, perhaps with dietary treatment, and will work independently of phenylalanine hydroxylase (PAH), correcting such forms of hyperphenylalaninemias regardless of the PAH mutations carried by the patient.